ZYUS Life Sciences Corporation ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 270.90K | 299.10K | 289.60K | 332.30K | 346.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 270.90K | 299.10K | 289.60K | 332.30K | 346.30K |
| Cost of Revenue | 311.80K | 311.10K | 299.90K | 1.07M | 1.03M |
| Gross Profit | -40.80K | -11.90K | -10.20K | -734.20K | -679.20K |
| SG&A Expenses | 5.39M | 5.87M | 6.00M | 5.98M | 6.09M |
| Depreciation & Amortization | 1.22M | 1.59M | 1.95M | 2.06M | 2.07M |
| Other Operating Expenses | 66.20K | 107.40K | 197.10K | 280.50K | 302.50K |
| Total Operating Expenses | 8.49M | 9.78M | 10.49M | 10.86M | 11.36M |
| Operating Income | -8.22M | -9.48M | -10.20M | -10.52M | -11.01M |
| Income Before Tax | -14.04M | -15.04M | -15.56M | -25.57M | -25.82M |
| Income Tax Expenses | -- | -- | -- | -1.46M | -1.47M |
| Earnings from Continuing Operations | -14.04 | -15.04 | -15.56 | -24.12 | -24.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.04M | -15.04M | -15.56M | -24.12M | -24.36M |
| EBIT | -8.22M | -9.48M | -10.20M | -10.52M | -11.01M |
| EBITDA | -7.29M | -8.18M | -8.55M | -8.79M | -9.27M |
| EPS Basic | -0.18 | -0.19 | -0.20 | -0.32 | -0.33 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.10 | -0.10 | -0.10 |
| EPS Diluted | -0.18 | -0.20 | -0.20 | -0.33 | -0.33 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.10 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 317.89M | 312.98M | 307.21M | 302.28M | 296.53M |
| Average Diluted Shares Outstanding | 317.89M | 312.98M | 307.21M | 302.28M | 296.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |